噻托溴铵在慢性阻塞性肺疾病中的应用进展  

Applications and advancements of tiotropium bromide in treatment of chronic obstructive pulmonary disease

作　　者：张彩霞[1] 杨炯[1] 

机构地区：[1]武汉大学人民医院呼吸内科,430060

出　　处：《国际呼吸杂志》2008年第7期433-435,共3页International Journal of Respiration

摘　　要：支气管扩张剂可减轻气流受限，被认为是改善慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）症状的主要治疗药物。目前随着药物研究的发展，长效抗胆碱能药物——噻托溴铵在COPD治疗中发挥了重要的作用。它能改善COPD患者肺功能，与其它支气管扩张剂疗效比较具有明显的优势，同时联合两种或两种以上其它不同作用机制的支气管扩张剂可增加支气管扩张程度而不增加不良反应，故被认为是COPD维持治疗的一线药物之一。Knowned as chief curatives to improve symptoms of chronic obstructive pulmonary disease （COPD）, bronchodilators can relieve airflow limitation. Nowadays, along with the developments of pharmacal investigation, long acting anticholinergic drug-tiotropium bromide plays an important role in the treatment of COPD. It can improve the lung function of COPD, has evident ascendancies in curative effect in comparing with other bronchodilators,can increase bronchiectasic extent but do not augment adverse effect in combinateing two or varied different bronchodilators in its mechanism. Therefore,it is knowned as one of the first-line drugs in the rnaintenane therapy.

关 键 词：慢性阻塞性肺疾病 抗胆碱能药物 噻托溴铵 支气管扩张剂 

分 类 号：R563.9[医药卫生—呼吸系统]